相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Aurobindo Pharma subsidiary Apitoria will acquire an 80% stake in A1 Biochem Group for USD 17 million, with the deal approved by Apitoria's board on July 23, 2026. - The acquisition brings front-end CRO capabilities including custom synthesis, medicinal chemistry, and analytical development, complementing Apitoria's existing large-scale API manufacturing. - A1 Biochem operates labs in Wilmington, North Carolina and Hyderabad, India, employs over 90 scientists, and has completed more than 800 projects for over 50 clients. - The transaction is expected to close within 90 to 120 days, subject to regulatory approvals, and will be funded entirely through cash consideration.
- Aurobindo Pharma's API manufacturing subsidiary Apitoria Pharma received a Voluntary Action Indicated (VAI) classification from the US FDA, indicating successful resolution of previous warning letter issues. - The FDA concluded its for-cause inspection of the Telangana facility with five procedural observations, determining that corrective actions adequately addressed prior regulatory concerns. - A separate formulations facility operated by subsidiary Eugia Pharma Specialities in Rajasthan received nine procedural observations following a November inspection. - The VAI classification represents a positive regulatory outcome, as it indicates the FDA is not prepared to take administrative or regulatory action against the facility.
